A Phase III, Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception from Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection (Polymerized Human Hemoglobin [Pyridoxylated], Polyheme) when Used to Treat Patients in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Prehospital Setting. Institutional Sub-investigator, 2003. Sponsor: Northfield Laboratories, Inc. I

4.

Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-Associated Pneumonia. Institutional Subinvestigator, July 2003. Sponsor: Astra-Zeneca.

5.

A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi- Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-Negative Severe Sepsis in Adults. Institutional Sub-investigator, November 2004. Sponsor: GlaxoSmithKline.

6.

DORI-07 A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem with that of Meropenem in Complicated Intra-abdominal Infections. Institutional Sub-investigator, November 2004. Sponsor: PPD Development.

Methodological Study in Adult Patients with Severe Sepsis to Assess the Feasibility and Logistics of Using Serological Samples to Assess and Characterize Selected Cytokine and Other Biomarker Assays. Institutional Sub-investigator, 2006. Sponsor: Astra Zeneca

A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 versus a Caspofungin Followed by Voriconazole Regimen in the treatment of Candidemia and Other Invasive Candida Infections. Institutional Sub-investigator, 2007. Sponsor: Basilea Pharmaceutica

23.

A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab™ (AZD9773) in Patients with Severe Sepsis. Institutional Sub-investigator, 2007. Sponsor: Astra Zeneca

24.

Linezolid in the Treatment of Subjects with Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus. Institutional Sub-investigator, 2007. Sponsor: Pfizer